Published in Bone Marrow Transplant on September 14, 2015
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Population screening in the age of genomic medicine. N Engl J Med (2003) 3.89
Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol (1991) 3.21
Hepcidin and disorders of iron metabolism. Annu Rev Med (2011) 2.67
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant (2014) 2.46
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood (2007) 1.78
Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.76
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab (2008) 1.55
Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study. Ann Hematol (2008) 1.53
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica (2012) 1.35
Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant (2008) 1.29
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res (2010) 1.23
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood (2011) 1.23
Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol (2008) 1.19
Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol (2012) 1.15
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res (2007) 1.10
Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood (2010) 1.09
Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant (2009) 1.04
Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Am J Hematol (1999) 1.03
Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant (2003) 1.02
Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. Ann Hematol (2009) 1.00
Review article: management of hepatic disease following haematopoietic cell transplant. Aliment Pharmacol Ther (2006) 0.99
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol (2008) 0.97
Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant (2000) 0.97
Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol (2012) 0.96
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol (2013) 0.95
A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant (2010) 0.93
The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. Transfus Apher Sci (2013) 0.92
Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant (2014) 0.91
The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant (2008) 0.90
Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. Br J Haematol (2011) 0.87
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Ann Hematol (2011) 0.86
Function of the hemochromatosis protein HFE: Lessons from animal models. World J Gastroenterol (2008) 0.85
Deferasirox reduces oxidative stress in patients with transfusion dependency. J Clin Med Res (2013) 0.85
Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading? Adv Hematol (2011) 0.85
Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant (2008) 0.83
SELDI-TOF MS detection of urinary hepcidin. Biochimie (2009) 0.83
Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. Ann Hematol (2013) 0.82
Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up. Oncol Lett (2013) 0.80
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer (2016) 0.78
Intravenous chelation therapy during transplantation for thalassemia. Haematologica (1995) 0.78
Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation. Am J Blood Res (2012) 0.78
The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2010) 0.78
Early iron reduction programme for thalassaemia patients after bone marrow transplantation. Bone Marrow Transplant (2000) 0.78
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica (2014) 0.77
Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin (2006) 0.76
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol (2009) 0.76
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia (2014) 1.05
Low frequency of calreticulin mutations in MDS patients. Leukemia (2014) 0.78
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant (2017) 0.75